BTAX.US Biostax Corp.
- Market cap
- USD 15.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2025.
Is BTAX.US undervalued?
Graham numberThe Graham number of Biostax Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biostax Corp. fundamental analysis
No fundamental analysis for Biostax Corp. yet.
Biostax Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biostax Corp.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to …
Full company profileBiostax Corp. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 4 quarters up to Mar 31, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biostax Corp. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Operating Income | -2.84M | -887K | -738K | -1.16M | -1.48M | -790K |
| EBITDA | - | 2.07M | 3.80M | -3.42M | -2.14M | - |
| Net Income | -3.40M | 1.59M | 3.59M | -3.54M | -2.36M | -853K |
| EPS | -7.42 | 3.44 | 0.38 | -0.10 | -0.03 | -0.01 |
| Balance Sheet | ||||||
| Total Assets | 5.82K | 10.2K | 3.14M | 964K | 35.3K | 5.50K |
| Total Liabilities | 13.7M | 11.7M | 11.1M | 3.48M | 4.56M | 5.33M |
| Shareholders' Equity | -13.7M | -11.7M | -7.95M | -2.51M | -4.53M | -5.32M |
| Cash & Short-term Investments | 4.93K | 9.97K | 3.14M | 150K | 29.8K | - |
| Total Debt | - | 2.84M | 3.07M | 696K | 1.13M | 1.16M |
| Cash Flow | ||||||
| Operating Cash Flow | -934.00 | -192K | -232K | -582K | -408K | -47.2K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 500K | 0.00 | 0.00 |
| Free Cash Flow | -934.00 | -192K | -232K | -1.08M | -408K | -47.2K |
| Ratios | ||||||
| ROA | -58,402.0% | 15,619.1% | 114.2% | -366.9% | -6,695.9% | -15,508.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Biostax Corp. dividends
Biostax Corp. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:1000 on May 6, 2021.
Who owns Biostax Corp.
- Insiders 57.76%
- Institutions 0.00%
- Public & others 42.24%
- Shares outstanding 78.7M
- Free float 53.5M
Biostax Corp. company profile
- Company name
- Biostax Corp.
- Ticker
- BTAX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 2431 Aloma Ave., Winter Park, FL, United States, 32804
- Phone
- 888 613 8802
- Website
- biostaxcorp.com
About Biostax Corp.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to manage and secure prescriptions and electronic health records; JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and Low Dose Naltrexone, a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging. The company also develops programs for the treatment of hyperphosphatemia. It has a licensing agreement with Cytocom Inc. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is headquartered in Winter Park, Florida.
Biostax Corp. management
6- Ms. Noreen M. GriffinFounder, Executive VP of Business Development & CEO · born 1953
- Ms. Kelly O'Brien WilsonPresident · born 1972
- Mr. Glen A. Farmer M.B.A.Chief Financial Officer · born 1969
- Mr. Robert WilsonVP of Strategy & Director · born 1973
- Ms. Cynthia DouglasCompany Secretary · born 1973
- Dr. Joseph M. FortunakVice President of Global Research & Development and Chemical Development · born 1955